Sysmex Corporation (TYO:6869)

Market Cap	987.81B -45.4%
Revenue (ttm)	498.69B +1.5%
Net Income	46.69B -12.7%
EPS	74.85 -12.6%
Shares Out	623.62M
PE Ratio	21.16
Forward PE	18.43
Dividend	36.00 (2.35%)
Ex-Dividend Date	Mar 30, 2026

Volume	8,989,400
Average Volume	3,387,220
Open	1,449.00
Previous Close	1,584.00
Day's Range	1,333.50 - 1,468.50
52-Week Range	1,334.00 - 2,934.00
Beta	0.68
RSI	32.11
Earnings Date	Feb 12, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 6869

Financial Performance

In fiscal year 2025, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.